Hims & Hers (HIMS) is presented as a strong buy opportunity due to its rapid revenue growth, international expansion via Eucalyptus, and the belief that current regulatory risks are already priced into the stock.
Source Post
Is Hims & Hers Health Inc HIMS A Good Time To Buy Now? HIMS Stock Analysis
Mar 15, 2026
This analysis of Hims & Hers Health (HIMS) highlights a significant disconnect between explosive revenue growth and a heavily discounted stock price. Despite facing legal and regulatory headwinds, particularly concerning GLP1 drugs, the company has doubled its revenue in two years and is projected for continued strong growth. The acquisition of Eucalyptus for international expansion and a focus on a personalized digital health platform are seen as key strengths. Analysts predict substantial upside, with the stock currently trading at a value multiple on hyper-growth. The core thesis is to buy now, believing regulatory risks are priced in ahead of expected strong Q4 earnings.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
HIMSbuy opened Mar 15, 2026
+18.37%